pHion Therapeutics is a therapeutic vaccine development company, utilising its patented peptide based drug delivery system, RALA, which when combined with nucleic acids, generates a uniquely potent therapeutic response without provoking an innate immune response.
pHion’s therapeutic vaccine programme is focused on viral infections as it evokes a strong interferon gamma response. We believe that the RALA vaccine technology marks the advent of a new generation of therapeutic vaccines that could clear infectious diseases on a global scale.
In addition to therapeutic vaccines, RALA possesses unique traits that will offer significant value in both oncology (tumour specific delivery) and in ex vivo gene therapy (nanoparticle formulation for AAV manufacture) applications.
Fast track your newest drug compound or nucleic acid target to the clinic by working with RALA to enhance in vitro and subsequent in vivo performance
Formulate your original lead compound into a bioavailable drug delivery system. With proven cellular entry, move quickly to valuable research, leading to more informed in vivo studies
Eliminate issues with nucleic acid size and associated scalability of your drug formulation. pHion's RALA system is not restricted by the size of your intended cargo, or in the scaling-up of manufacture of your final compound
Get the most out of your compound by increasing the bioavailability profile. pHion's RALA drug delivery system is the first system with an ability to concentrate nucleic acids and other anionic compounds into cells in a non-toxic manner due to the presence of natural amino acids
Increase the therapeutic potential of your nucleic acid vaccine by partnering with pHion and taking advantage of all the benefits of the RALA nanoparticle system
Increase the viral titre of your AAV production through the use of RALA-V, an optimised RALA nanoparticle system for the creation of AAV particles
MEET THE TEAM
The pHion Therapeutics team includes inventors, scientists and legal staff from Queen's University Belfast and a wide variety of industry landscapes.
We believe that the individuals behind pHion Therapeutics represent the best minds investigating non-toxic cell penetrating peptides for drug delivery.
They stand ready to support the numerous and varied applications of RALA.
BOARD OF DIRECTORS
BOARD OF DIRECTORS
LYN ROSENBRIER SCIENTIFIC CONSULTANT
NICHOLAS DUNNE SCIENTIFIC CONSULTANT
SARAH BROCKBANK SCIENTIFIC CONSULTANT
STEPHEN LIGGETT REGULATORY CONSULTANT
TRACY ROBSON. SCIENTIFIC CONSULTANT